Featured Content

Winston, Wong, PharmD
President, W-Squared Group

Antiemetics Overused in Patients With Cancer at Low Risk for CINV

(Medscape Medical News) Sept 23, 2016 - Antiemetics are overused in patients with cancer receiving chemotherapy, and this overuse results in unnecessary spending associated with chemotherapy treatment, assert researchers reporting a new study that looked at the impact of Choosing Wisely recommendations.

Commentary: These findings appear to be similar to a study looking at colony stimulating factors back in 2011, showing 50%...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next

(TheStreet) Sept 26, 2016 - Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.
read article »

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

(TheStreet) Sept 27, 2016 - A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
read article »

Amgen's Multiple Myeloma Drug Falls Short In New-Patient Study

(Reuters) Sept 27, 2016 - Amgen Inc said on Tuesday its multiple myeloma drug, Kyprolis, did not fare better than Takeda Pharmaceutical Co Ltd's older therapy Velcade in a study involving patients who had not yet been treated for the disease.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Antiemetics Overused in Patients With Cancer at Low Risk for CINV (Medscape Medical News)

These findings appear to be similar to a study looking at colony stimulating factors back in 2011, showing 50%...posted by: Winston, Wong, PharmD

Precision Medicine Trial First Of Its Kind To Show Benefit To Patients (ESMO)

Far too many people do not look critically at precision medicine claims and are only looking for the slightest...posted by: H. Jack, West, MD

Novartis Announces Positive Top-Line Results From ASCEND-4, a Phase III Trial of Zykadia® In Untreated Adult ALK+ NSCLC Patients (Novartis)

This positive trial will likely have no impact (and shouldn't). Ceritinib is currently quite disfavored because...posted by: H. Jack, West, MD

CMS Announces Changes in MACRA Implementation Timeline (ASH)

The announced changes in the timeline for implementation of payment aspects and programs authorized under MACRA...posted by: William McGivney, PhD

UCLA Study Finds Common Breast Cancer Test May Not Be Worth The Cost (UCLA/Jonsson CCC)

Was the savings from eliminating a course of Radiation Therapy or adjuvant chemotherapy in these women considered?...posted by: Barbara Schlager MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Navigating Cancer has 1 job posted.


Bayer Pharmaceuticals has 1 job posted.


Touchpoint Solutions has over 20 jobs posted.


Check out the OBR Job Board here.





The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
JUNO +12.72%
CCXI +11.81%
CLDX +11.32%
IDRA -6.77%
FATE -4.40%
NKTR -3.77%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: September 2016
Company: Kite Pharma
Product: KTE-C19

Date: October 10, 2016
Company: Exelixis Inc.
Product: cabozantinib

Date: October 19, 2016
Company: Roche / Genentech
Product: Tecentriq® (atezolizumab)

See All OBR Radar items»